These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 31016167

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis.
    Sinha B, Ghosal S.
    Diabetes Ther; 2019 Jun; 10(3):891-899. PubMed ID: 30875065
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The safety of gliptins : updated data in 2018.
    Scheen AJ.
    Expert Opin Drug Saf; 2018 Apr; 17(4):387-405. PubMed ID: 29468916
    [Abstract] [Full Text] [Related]

  • 29. Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis.
    Cai RP, Xu YL, Su Q.
    Cardiol Res Pract; 2021 Apr; 2021():6657380. PubMed ID: 33859839
    [Abstract] [Full Text] [Related]

  • 30. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K, Gräber S.
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [Abstract] [Full Text] [Related]

  • 31. The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review.
    Taylor OM, Lam C.
    Curr Ther Res Clin Exp; 2020 Dec; 93():100596. PubMed ID: 32817765
    [Abstract] [Full Text] [Related]

  • 32. Effect of Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Events in Type-2 Diabetes Patients with Renal Impairment: A Systematic Review and Meta-analysis.
    Khalse M, Ganapathy B.
    Indian J Endocrinol Metab; 2020 Dec; 24(2):143-149. PubMed ID: 32699780
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Zhang F, Xu S, Tang L, Pan X, Tong N.
    Front Endocrinol (Lausanne); 2020 Dec; 11():288. PubMed ID: 32582019
    [Abstract] [Full Text] [Related]

  • 35. Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.
    Fu AZ, Johnston SS, Ghannam A, Tsai K, Cappell K, Fowler R, Riehle E, Cole AL, Kalsekar I, Sheehan J.
    Diabetes Care; 2016 May; 39(5):726-34. PubMed ID: 26740636
    [Abstract] [Full Text] [Related]

  • 36. SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
    Singh AK, Singh R.
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):429-442. PubMed ID: 28121469
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease.
    Schuetz CA, Ong SH, Blüher M.
    Clinicoecon Outcomes Res; 2015 Apr; 7():313-23. PubMed ID: 26089691
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.